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Abstract
Background: Acute interstitial nephritis (AIN) represents a frequent cause of acute kidney injury. While many
etiologies of AIN have been recognized, the majority (60–70 %) are due to allergic reactions or drug exposure.
Many different classes of drugs and several agents within a class can cause drug induced AIN. Flecainide, a class Ic
antiarrhythmic drug, had thus far not been associated with the occurrence of AIN.
Case presentation: Here we describe a case of biopsy proven AIN after flecainide therapy in a pregnant patient.
The 24-year old Caucasian woman was admitted to our university hospital for a planned c-section. She had been
put on flecainide at a dose of 200 mg/d for supraventricular tachyarrhythmia of the fetus ten days earlier. The only
fleaainide drug level was obtained 24 h after the last dose. At this time point the serum level was still in the
therapeutic range (392 ng/mL). After hospital admission the patient underwent uneventful c-section and delivered
a 3095 g baby girl with mild insufficiency of the tricuspid valve. In the hours following the c-section, a single dose
of the non-steroidal anti-inflammatory drug (NSAID) ibuprofen (600 mg) as well as single dose of diclofenac
(100 mg) was administered. Within 5 days after c-section her baseline creatinine of 30 μmol/L increased to
277 μmol/L. The serum creatinine continued to rise to 411 μmol/L on hospital day # 7. On renal ultrasound kidneys
were enlarged and swollen. Urinary sediment at this point only revealed slight proteinuria (506 mg/g creatinine). A
renal biopsy was performed showing acute interstitial nephritis. Within four days the renal function improved after
discontinuation of flecainide and NSAIDs even without steroid therapy and the patient was discharged with a
creatinine of 88 μmol/L after 13 days in the hospital.
Conclusion: This case suggests that flecainide, at least in combination with NSAIDs, can cause AIN.
Background
Acute interstitial nephritis (AIN) represents a frequent
cause of acute kidney injury. While many etiologies of
AIN have been recognized, the majority (60–70 %) are
due to allergic reactions or drug exposure [1]. Many dif-
ferent classes of drugs can cause AIN ranging from more
frequent ones like antimicrobials (ampicillin, ciprofloxa-
cin, methicillin, rifampicin and sulfonamides) and non-
steroidal anti-inflammatory drugs (acetylsalicylic acid,
ibuprofen, naproxen) over proton pump inhibitors
(omeprazole and pantoprazole) [1] to rarer causes like
newer quinolones (moxifloxacin) [2] and/or iron
chelating agents such as deferasirox [3]. Flecainide, a
class Ic antiarrhythmic drug, had thus far not been asso-
ciated with the occurrence of AIN. It is used to treat a
variety of cardiac arrhythmias including paroxysmal
atrial fibrillation, paroxysmal supraventricular tachycar-
dia and ventricular tachycardia. During pregnancy, fle-
cainide is used to treat refractory fetal tachycardia. It
blocks sodium channels in the heart, causing prolonga-
tion of the cardiac action potential. The majority of fle-
cainide is eliminated by the kidneys, with the remainder
metabolized by the cytochrome P450 2D6 isoenzyme in
the liver [4]. Despite the narrow therapeutic index of
flecainide reflected by the fact that the toxic effects
of flecainide are closely related to the plasma levels
of the drug [5], therapeutic drug monitoring is not
regularly performed.
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Case presentation
Here we describe a case of biopsy proven AIN after a
10 day flecainide therapy and a single dose NSAIDs in a
pregnant patient. Due to fetal tachycardia the 24-year
old woman (height 162 cm, weight 86.7 kg) was put on
flecainide therapy in the 36th week of gestation (G2P0).
Ten days later she was admitted to our university hos-
pital for a planned c-section due to fetal heart failure.
On admission she reported no complaints. The blood
pressure was 109/72 mmHg and the heart rate was 108
beats per minute. The remainder of the physical exam
was unremarkable. She denied any regular medication
other than vitamin supplementation. Laboratory evalu-
ation showed a slightly increased alkaline phosphatase of
134 U/L. The serum creatinine was 30 μmol/L. Her
prior medical history was significant for two events of
peripheral self-limiting facial nerve palsy. In the cardio-
tocography the fetal heart rate was 187 beats per minute.
It also showed signs of slight uterus contractions. Fetal
ultrasound revealed hypertrophic cardiomyopathy and
tricuspid valve insufficiency grade two. One day after
discontinuation of her 10 day flecainide therapy, her
serum level was 391 ng/mL (therapeutic range 300–
1000 ng/mL) confirming adherence to the prescribed
medication. At the day of delivery our patient received a
single dose of the non-steroidal anti-inflammatory drug
(NSAID) ibuprofen (600 mg) as well as single dose of
diclofenac (100 mg). Within five days after delivery her
baseline creatinine rose from 30 to 277 μmol/L. The
same day treatment with cefotaxime was started for
suspected urinary tract infection accompanied by a C-
reactive protein (CRP) level of 68 mg/L. Despite the fall
in inflammatory parameters serum creatinine continued
to rise up to 411 μmol/L on hospital day # 7 (Fig. 1). On
renal ultrasound, kidneys were enlarged and swollen
(323 ml for the right and 326 ml for the left kidney).
There were no signs of post-renal AKI. Urinalysis
showed proteinuria, hemoglobinuria and leukocyte ester-
ase. Urinary sediment at this point only revealed slight
proteinuria (506 mg/g creatinine) and white blood cells
(28/μl). Red blood cells or urinary casts were not detect-
able. Renal biopsy was performed on hospital day # 10
(nine days after delivery). Light microscopy (Fig. 2) re-
vealed AIN. About 30 % of cortex and 10 % of medulla
were infiltrated by a mixed infiltrate of lymphocytes, his-
tiocytes, a few plasma cells and a maximum of 40 eo-
sinophilic granulocytes. Beside this infiltrate there were
also some scattered fibroblasts producing the matrix
Fig. 1 Serum creatinine CRP levels of a pregnant patient during outpatient visits as well as during the hospital course/treatment of AIN due to
flecainide (and NSAID). c-sec = c-section. Renal Bx = renal biopsy
Fig. 2 Kidney biopsy (HE Stain, 100 X)
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detected. However there were also many widened peri-
tubular capillaries indicating a predominant AIN. Al-
most all tubules of the cortex were severely flattened
and demonstrated a severe loss of the brush border,
which highlighted a severe tubular damage. Furthermore
focal areas of tubulitis of three intraepithelial lympho-
cytes per ten tubular epithelial cells (matching t1 accord-
ing to Banff ) were found. Within six days the renal
function improved even without steroid therapy and the
patient was discharged with a creatinine of 88 μmol/L
after 13 days in the hospital (Fig. 1). Considering the low
grade evidence supporting steroid treatment in AIN and
given the spontaneous resolution of renal dysfunction
with simple discontinuation of the offending agents, ste-
roids were not deemed necessary.
Discussion
Here we report to our knowledge the first case of biopsy
proven AIN due to flecaininde. So far there is only one
report on acute kidney injury in relation to flecainide
overdose published. Meurin and co-workers describe a
case of AKI after initiating therapy with NSAID as a co-
medication of flecainide and an ACE-inhibitor [6]. In
their report the 76 year old patient was on flecainide
therapy (200 mg/d) for three years. Fifteen days after ini-
tiation of treatment with indomethacin (125 mg/d) their
patient presented with a serum creatinine of 300 μmol/L.
After discontinuation of the indomethacin and flecainide
the patient’s creatinine decreased to 153 μmol/L within
two weeks.
In contrast to the former study, in which no renal bi-
opsy was performed, we did prove the diagnosis by renal
biopsy. Moreover, we also performed a post hoc analysis
of the flecainide level. About 24 h after the last dose of
flecainide the serum level was 390 ng/mL, which is well
within the therapeutic range of 300–1000 ng/mL. Given
the fact that the half-life of flecainide is about 20 h
(60–70 hours in patients with severe kidney damage),
it is possible that the drug level during treatment was
within the supratherapeutic range. The recommended
daily dose of flecainide in the therapy of supraventric-
ular arrhythmia is 300 mg/d at most and should be
well monitored in patients with impaired kidney func-
tion. Our case suggests that flecainide, at least in
combination with NSAIDs, can cause AIN due to its
renal elimination and severe toxicity after overdosage
[7]. Above and beyond the inherent limitations of a
case report we cannot exclude that the single dose of
two NSAIDs (600 mg ibuprofen and 100 mg diclofe-
nac) administered on the day of delivery, caused the
AIN alone. This holds especially true as we do not
have daily creatinine levels. The fact that the patient
only received a single (rather low) dose of NSAIDs
but was on fleacainide therapy for 10 days with at
drug levels well in the therapeutic range even 24 h
after discontinuation, which we consider to be sug-
gestive of an potential overdose, makes us lean to-
wards a causative role for flecainide. It may well be
that the combination of a single dose NSAIDS on top
of a 10 day therapy with flecainide caused AIN.
Conclusion
In terms of pharmacovigilance clinicians should be aware
of the potential side effect of flecainide (in combination
with NSAIDs) and monitor renal function regularly. An
alternative approach would be to avoid NSAIDs in pa-
tients treated with flecainide altogether, especially since
there are many alternatives available that are not associ-
ated with an increased risk for AIN.
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